Last reviewed · How we verify
Abrocitinib 200 mg (abrocitinib-200-mg)
Abrocitinib 200 mg (generic name: abrocitinib-200-mg) is a JAK inhibitor drug developed by Pfizer. It is currently FDA-approved for Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy.
Abrocitinib is a small molecule inhibitor of the tyrosine-protein kinase JAK1. It is being studied for various conditions, including Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and has also been studied in a Phase 1 trial to assess its effect on rosuvastatin pharmacokinetics in healthy participants.
At a glance
| Generic name | abrocitinib-200-mg |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK1 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| Annual revenue | 284 |
Approved indications
- Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy
Common side effects
Drug interactions
- Warfarin
- Live vaccines
- Bacillus Calmette-Guérin (BCG) vaccine
- Other vaccines
- Interferon-alpha
- Interferon-beta
- Interferon-gamma
- Other immunosuppressants
- Methotrexate
- Azathioprine
- Cyclosporine
- Tacrolimus
Key clinical trials
- Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy (PHASE2)
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome (PHASE2)
- Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (PHASE3)
- Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) (PHASE2)
- Janus Kinase Inhibition in Sarcoidosis (PHASE2)
- Janus Kinase Inhibition in Granuloma Annulare (PHASE2)
- A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (PHASE1)
- A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abrocitinib 200 mg CI brief — competitive landscape report
- Abrocitinib 200 mg updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Abrocitinib 200 mg
What is Abrocitinib 200 mg?
What is Abrocitinib 200 mg used for?
Who makes Abrocitinib 200 mg?
What is the generic name of Abrocitinib 200 mg?
What drug class is Abrocitinib 200 mg in?
What development phase is Abrocitinib 200 mg in?
What is Abrocitinib 200 mg's annual revenue?
What does Abrocitinib 200 mg target?
Related
- Drug class: All JAK inhibitor drugs
- Target: All drugs targeting JAK1
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing